Advertisement

Topics

Boehringer Ingelheim, MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases

15:00 EST 9 Nov 2017 | Drug Discovery Development

NASH is a major cause of liver fibrosis and cirrhosis and an area of high unmet medical need.
Contributed Author: 
Topics: 

Original Article: Boehringer Ingelheim, MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim, MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...